View Older Stories View More Recent Stories
-
Form 424B2 CITIGROUP INC
-
Form 424B2 CITIGROUP INC
-
Form 424B2 CITIGROUP INC
-
Form 424B8 CITIGROUP INC
-
Form 424B2 CITIGROUP INC
-
Form 424B2 CITIGROUP INC
-
Form 424B2 CITIGROUP INC
-
Form 424B2 CITIGROUP INC
-
Writer Raises $200M Series C at $1.9B Valuation to Fuel Leadership in Agentic Enterprise AI
-
Lumen Announces Any and All Cash Tender Offers for Unsecured Notes of Lumen and Level 3
-
Better for All Joins Oak View Group's GOAL Network to Drive Sustainability at Major U.S. Venues
-
Analysis-German government collapse could have silver lining for Europe's markets
-
IHS Holding Limited (IHS) Announces Potential Dual-Tranche Senior Notes Offering
-
IHS Holding Limited Announces Potential Dual-Tranche Senior Notes Offering
-
Citizen Satisfaction With Federal Government Hits 7-Year High, ACSI Data Show
-
LENZ Therapeutics to Participate in Upcoming Investor Conferences
-
Vega Raises $20 Million Series A Led by Apollo and Motive to Scale AltOS – The New “Core” for Private Markets Client Service
-
Foghorn Therapeutics to Participate in Three Upcoming Investor Conferences
-
NCIG Announces Cash Tender Offers for Certain Outstanding Debt Securities
-
Citi Pounds Table on US Semis, Says Worst Nearly Over, 'Almost time to buy again'
-
Taylor Morrison Home (TMHC) Appoints Fletcher Previn to its Board
-
Cisco Executive to Join Taylor Morrison Board of Directors
-
Apple and these 8 stocks could be most hit by China tariffs
-
Immersive Labs Unveils GenAI-Powered Cyber Exercise Creator to Rapidly Prepare Workforces for Threats
-
Grab Holdings Inc. (GRAB) PT Raised to $5.90 at Citi
-
Citi Upgrades Carter's (CRI) to Neutral
-
Citi Downgrades RXO, Inc. (RXO) to Neutral
-
Citi Downgrades Ross Stores, Inc. (ROST) to Neutral
-
Citi Downgrades Knight Transportation (KNX) to Sell
-
Citi Upgrades Canadian National Railway (CNI) to Buy
-
Citi Upgrades C.H. Robinson Worldwide (CHRW) to Buy
-
Highlights from ruling in Shell's climate case
-
Citi Reiterates Neutral Rating on Fortinet (FTNT)
-
Huhtamaki signed a EUR 450 million sustainability-linked syndicated revolving credit facility
-
Shell wins appeal against landmark Dutch climate ruling
-
Vistry Group PLC (VTY:LN) PT Lowered to GBP8.43 at Citi
-
Diploma Plc. (DPLM:LN) PT Raised to GBP49 at Citi
-
Citi Upgrades Geberit AG (GEBN:SW) (GBERY) to Neutral
-
Citi Downgrades Venture Corp Ltd. (VMS:SP) (VEMLF) to Neutral
-
Citi Resumes Tata Motors Ltd. (TTMT:IN) at Buy
-
Citi Downgrades Semen Indonesia Persero Tbk PT (SMGR:IJ) (PSGTY) to Sell
-
Citi Starts KPJ Healthcare Bhd (KPJ:MK) at Buy
-
Cardinal Health announces two strategic additions to its portfolio
-
Aristocrat sells 'RAID: Shadow Legends' developer for $820 million
-
Lithium Royalty Corp. Reports Q3 2024 Results
-
Citi Reiterates Buy Rating on Permian Resources Corp (PR)
-
Transaction in Own Shares
-
Criterion Real Estate Capital Adds Industry Veterans Adam Matos and Ben Milde to Leadership Team
-
Citius Pharmaceuticals (CTXR) and Citius Oncology (CTOR) Report Prelim Results of an Investigator-Initiated Phase I Clinical Trial of Pembrolizumab and LYMPHIR
-
Citius Pharmaceuticals, Inc. and Citius Oncology, Inc. Announce Promising Preliminary Results of an Investigator-Initiated Phase I Clinical Trial of Pembrolizumab (KEYTRUDA®) and LYMPHIR™ in Cancer
